Aclaris Q3 net loss $29.3M, revenue $9.3M; zunsemetinib RA data due Nov 2023

Aclaris Therapeutics, Inc.

2023-Q3 EPS reported -$1.25 revenue$13,679,000

Net loss of $29.3M for Q3 2023 compared to $20.0M in Q3 2022.
Total revenue $9.3M, down from $19.0M due to prior year Lilly payment.
Cash and securities $187.0M as of Sept 30, 2023; sufficient through end of 2025.
Zunsemetinib Phase 2b RA topline data expected November 2023.
ATI-1777 Phase 2b AD data expected around year-end 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aclaris Therapeutics, Inc. reported third quarter of 2023 results: revenue $9.3 million, net income net loss was $29.3 million.

Period: third quarter of 2023
Revenue: $9.3 million
Net income: net loss was $29.3 million
Result: reported results

Exact text from the filing

Results Third Quarter 2023 ● Net loss was $29.3 million for the third quarter of 2023 compared to $20.0 million for the third quarter of 2022. ● Total revenue was $9.3 million for the third quarter of 2023 compared to $19.0 million for the third quarter of 2022. The decrease was primarily driven by a one-time upfront payment under the non-

View on SEC.gov

Browse all earnings releases →

Aclaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-017655

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.